Indiplon For the treatment of insomnia In 1998, DOV licensed indiplon from Wyeth-Ayerst and subsequently sublicensed it to Neurocrine Biosciences, Inc. Neurocrine is currently conducting Phase III clinical trial testing on this product candidate for the treatment of insomnia. Indiplon, is a non-BDZ that is reported to be more potent than currently marketed non-BDZs, and more selectively targets the specific GABAA receptor subtype believed to be responsible for promoting sleep. Neurocrine is currently developing both an immediate release formulation and a modified release formulation of indiplon to address the different needs of the insomnia patient population. Neurocrines clinical studies have shown that patient blood levels of indiplon reach their highest point approximately 30 minutes after ingestion followed by rapid removal from the blood stream to the point that it cannot be detected four hours later. Neurocrine has completed 19 Phase I and Phase II clinical trials of indiplon for efficacy and safety involving more than 1,100 subjects. Its current Phase III program is reported to involve approximately 3,500 additional subjects in eight large clinical trials. The first Phase III clinical trial, which commenced in November 2001, involves approximately 500 patients to evaluate an immediate release formulation of indiplon for the long-term treatment of chronic insomnia. The preceding description of Neurocrines clinical development of indiplon is based on their public disclosures, for further publicly disclosed information please go to www.Neurocrine.com.